To identify therapeutic targets in NAFLD-HCC, we performed an integrated analysis of NAFLD-HCC transcriptomic sequencing11 and gene essentiality datasets,12 unraveling the m6A writer METTL3 as a potential therapeutic target in NAFLD-HCC. The gene discussed is METTL3; the disease is metabolic dysfunction-associated steatotic liver disease.